Rhenman & Partners Asset Management’s Charles River Laboratories CRL Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13M	Buy	57,200 +31,200	+120%	+$5.56M	1.22%	36
2026 Q1	$4.49M	Buy	26,000 +4,000	+18%	+$742K	0.55%	59
2025 Q4	$4.39M	Buy	+22,000	New	+$3.99M	0.41%	66
2025 Q1	–	Sell	-14,850	Closed	-$2.74M	–	96
2024 Q4	$2.74M	Sell	14,850 -22,650	-60%	-$4.36M	0.28%	72
2024 Q3	$7.39M	Buy	37,500 +3,500	+10%	+$727K	0.6%	54
2024 Q2	$7.02M	Buy	34,000 +21,300	+168%	+$4.83M	0.67%	43
2024 Q1	$3.44M	Sell	12,700 -25,300	-67%	-$6.04M	0.33%	61
2023 Q4	$8.98M	Sell	38,000 -6,000	-14%	-$1.18M	0.9%	42
2023 Q3	$8.62M	Buy	+44,000	New	+$9.03M	0.93%	37

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Rhenman & Partners Asset Management's CRL Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Charles River Laboratories (CRL) stake by 120% in Q2 2026, buying an estimated $5.56M and bringing the position to 57,200 shares worth $13M. The position accounts for 1.22% of the portfolio, ranked #36.

Rhenman & Partners Asset Management first reported a position in CRL in Q3 2023 and has held it in 9 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Rhenman & Partners Asset Management held 57,200 shares of Charles River Laboratories worth $13M as of Q2 2026.
Rhenman & Partners Asset Management bought 31,200 Charles River Laboratories shares in Q2 2026, an estimated $5.56M.
Charles River Laboratories made up 1.22% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #36 holding.
Rhenman & Partners Asset Management first reported a position in Charles River Laboratories in Q3 2023 and has held it in 9 quarters since.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.